U.S. Capital Wealth Advisors LLC Purchases Shares of 7,902 Walgreens Boots Alliance, Inc. (NASDAQ:WBA)

U.S. Capital Wealth Advisors LLC bought a new position in Walgreens Boots Alliance, Inc. (NASDAQ:WBA) during the fourth quarter, Holdings Channel reports. The firm bought 7,902 shares of the pharmacy operator’s stock, valued at approximately $206,000.

Other institutional investors also recently bought and sold shares of the company. EverSource Wealth Advisors LLC grew its stake in shares of Walgreens Boots Alliance by 308.4% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,119 shares of the pharmacy operator’s stock worth $25,000 after purchasing an additional 845 shares during the period. Highlander Capital Management LLC purchased a new stake in Walgreens Boots Alliance during the fourth quarter worth $26,000. Venturi Wealth Management LLC grew its position in Walgreens Boots Alliance by 1,241.8% during the fourth quarter. Venturi Wealth Management LLC now owns 1,060 shares of the pharmacy operator’s stock valued at $28,000 after buying an additional 981 shares during the period. Rocky Mountain Advisers LLC purchased a new position in Walgreens Boots Alliance in the fourth quarter valued at $30,000. Finally, Tyler Stone Wealth Management raised its position in shares of Walgreens Boots Alliance by 1,280.0% in the third quarter. Tyler Stone Wealth Management now owns 1,380 shares of the pharmacy operator’s stock worth $31,000 after acquiring an additional 1,280 shares during the period. 58.59% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Walgreens Boots Alliance

In related news, CFO Manmohan Mahajan purchased 6,000 shares of Walgreens Boots Alliance stock in a transaction that occurred on Tuesday, April 2nd. The stock was purchased at an average cost of $19.38 per share, with a total value of $116,280.00. Following the completion of the transaction, the chief financial officer now directly owns 166,969 shares in the company, valued at $3,235,859.22. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CFO Manmohan Mahajan acquired 6,000 shares of the firm’s stock in a transaction dated Tuesday, April 2nd. The stock was acquired at an average cost of $19.38 per share, with a total value of $116,280.00. Following the completion of the acquisition, the chief financial officer now owns 166,969 shares of the company’s stock, valued at $3,235,859.22. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Inderpal S. Bhandari purchased 3,000 shares of Walgreens Boots Alliance stock in a transaction that occurred on Thursday, April 11th. The stock was acquired at an average price of $18.05 per share, with a total value of $54,150.00. Following the transaction, the director now owns 3,000 shares in the company, valued at $54,150. The disclosure for this purchase can be found here. 17.40% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms have recently commented on WBA. Morgan Stanley cut their price objective on Walgreens Boots Alliance from $21.00 to $20.00 and set an “underweight” rating for the company in a research report on Monday, April 1st. TD Cowen cut their target price on shares of Walgreens Boots Alliance from $37.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, April 3rd. Deutsche Bank Aktiengesellschaft lowered their price objective on Walgreens Boots Alliance from $23.00 to $22.00 and set a “hold” rating on the stock in a report on Wednesday, April 3rd. HSBC reissued a “reduce” rating and set a $20.00 target price (down previously from $27.00) on shares of Walgreens Boots Alliance in a report on Tuesday, February 20th. Finally, Leerink Partnrs reiterated a “market perform” rating on shares of Walgreens Boots Alliance in a research report on Monday, February 26th. Four equities research analysts have rated the stock with a sell rating, ten have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $24.36.

Walgreens Boots Alliance Stock Performance

NASDAQ:WBA opened at $17.23 on Thursday. The company has a market cap of $14.86 billion, a price-to-earnings ratio of -2.46, a price-to-earnings-growth ratio of 1.10 and a beta of 0.80. The company has a quick ratio of 0.32, a current ratio of 0.66 and a debt-to-equity ratio of 0.50. Walgreens Boots Alliance, Inc. has a 52 week low of $17.21 and a 52 week high of $32.89. The company has a fifty day simple moving average of $19.43 and a two-hundred day simple moving average of $21.53.

Walgreens Boots Alliance (NASDAQ:WBA) last released its earnings results on Thursday, March 28th. The pharmacy operator reported $1.20 EPS for the quarter, topping the consensus estimate of $0.82 by $0.38. Walgreens Boots Alliance had a positive return on equity of 12.11% and a negative net margin of 4.18%. The firm had revenue of $37.05 billion during the quarter, compared to analysts’ expectations of $35.86 billion. During the same period in the previous year, the firm posted $1.16 EPS. Walgreens Boots Alliance’s revenue for the quarter was up 6.3% on a year-over-year basis. As a group, equities analysts anticipate that Walgreens Boots Alliance, Inc. will post 3.23 earnings per share for the current fiscal year.

Walgreens Boots Alliance Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 12th. Investors of record on Tuesday, May 21st will be issued a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a yield of 5.80%. The ex-dividend date of this dividend is Monday, May 20th. Walgreens Boots Alliance’s dividend payout ratio (DPR) is -14.29%.

Walgreens Boots Alliance Profile

Walgreens Boots Alliance, Inc operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise.